neurotoxicity in the case of stroke treatment with tPA. 5, 6 In addition, thrombolytics are rapidly neutralized, and their large size hampers clot penetration, causing a delay in restoring perfusion. 7 Further research is warranted to improve the safety and efficacy of fibrinolytic therapy. Antibodies as tools to deliver thrombolytic drugs specifically to developing and existing clots are a promising alternative for locally enhanced potency and reduced side effects.
Platelets play a key role in thrombus formation 3 and are, therefore, a target of interest for combination with thrombolytic therapy. Targeting the fibrinogen receptor glycoprotein (GP) IIb/IIIa on platelets has been extensively studied for the prevention of platelet aggregation and has led to the reduction of ischemic complications, [8] [9] [10] especially in patients undergoing percutaneous coronary intervention. However, in large clinical trials, contradictory to its anticipated therapeutic effects, the administration of GPIIb/IIIa receptor blockers in combination with fibrinolytic agents has shown little improvement in mortality, mainly because of excess bleeding, 11, 12 limiting the broader utilization of the combination of GPIIb/IIIa inhibition and fibrinolysis. This can be, in part, attributed to the fact that all currently available GPIIb/IIIa inhibitors target the receptor regardless of the activation status, thereby causing complete systemic inhibition of platelet aggregation and firm adhesion. In addition, the ligand mimetic properties of clinically used GPIIb/IIIa inhibitors also can lead to paradoxical platelet activation imitating ligand-induced outsidein signaling. 13, 14 We have previously addressed these issues by generating conformation-specific small recombinant singlechain antibody fragments (scFv) that only target the activated GPIIb/IIIa receptor on platelets, avoiding outside-in signaling and allowing effective platelet inhibition without prolonging bleeding time. 15 , 16 The potential of these scFvs to be used as targeting tools has been demonstrated by their use in noninvasive diagnostic molecular imaging of thrombosis and inflammation. [17] [18] [19] Here, we use the targeting potential of a specific single-chain antibody SCE5, which selectively binds activated GPIIb/IIIa, to enrich the plasminogen activator scuPA at the site of platelet activation. We describe the recombinant fusion of this scFv to scuPA and the in vitro and in vivo testing of this novel targeted drug. This therapeutic approach facilitates highly effective thrombolysis without prolonging bleeding time. In addition, the described ability to inhibit thrombus formation together with the effective targeting at low systemic concentration could potentially allow the unique application of a fibrinolytic drug in a thromboprophylactic approach.
Methods
A detailed description of methods is provided in the Online Data Supplement.
Generation, Expression, and Purification of scFVs and scuPAs
Two different scFvs (activated GPIIb/IIIa-targeted scFv SCE5 and nontargeted scFv mut ) were fused with active scuPA and cloned into the pSectag2A vector system. Briefly, both scFv-scuPA plasmid constructs were produced using the human embryonic kidney cells (H293F) suspension culture. All scFv-scuPAs contain a 6x His-tag, which was used for purification with nickel-based metal affinity chromatography (Invitrogen).
Evaluation of the scFv-scuPA Constructs
The purity of the proteins was analyzed using SDS-PAGE and Western blotting. Anti-6x His-tag antibody horseradish peroxidase was used to detect the purified scFv-scuPA constructs. The scuPA in the fusion protein was converted to the active form using plasmin to cleave the Lys-158 to Ile-159 bond.
Static Adhesion Assay
The specificity of scFv SCE5 targeting activated GPIIb/IIIa was demonstrated using Chinese hamster ovary (CHO) cells that were either expressing activated GPIIb/IIIa integrin, nonactivated GPIIb/IIIa, or not expressing the GPIIb/IIIa integrin. Cells were grown to confluency in 6-well plates (BD Bioscience), incubated with purified scFv-scuPAs, followed by anti-Penta-His AlexaFluor 488-conjugated monoclonal antibody (anti-His-488; Qiagen, Germany). Cells were visualized with the IX81 Olympus microscope (Olympus, Japan) and Cell^P 1692 (ANALysis Image Processing) software.
Flow Cytometry
Platelet-rich plasma (PRP) was obtained from healthy volunteers. Diluted PRP was either not activated or activated with 20 μmol/L ADP, 5 μg/mL collagen-related peptide, or 30 μmol/L thrombin receptor-activating peptide before incubation with the purified scFv constructs, followed by anti-His-488 for detection. The activity of platelets was determined by FITC-labeled fibrinogen, PAC1-FITC, and CD62P-PE. The specificity of scFv SCE5 targeting activated platelets was analyzed using FITC-labeled fibrinogen and PAC1-FITC. Competitive assays were performed using abciximab (ReoPro) and FITC-labeled fibrinogen. Samples were fixed with 1x Cellfix (BD Bioscience) and analyzed by FACS Calibur (BD Bioscience). In addition, GPIIb/IIIa-expressing CHO cells were also used for flow cytometry.
Urokinase Activity Assay
Urokinase activity was determined with a chromogenic substrate assay. A comparison between clinically used uPA (Medac GmbH, Germany) and scFv-scuPA was made on the basis of equal urokinase activity. About 100 nmol/L of scFv-scuPA was monitored against urokinase standards (0-100 U/mL) used as positive controls. Plasmin was added to activate scuPA. S2444 (Chromogenix, Italy) was added, and samples were measured on a Victor3V Multi-label counter (PerkinElmer) at a wavelength of 405 nm.
Plasmin Activity Assay
The conversion of plasminogen to plasmin using commercial uPA or the 2 scFv-scuPA versions was determined in microtiter plates using a chromogenic substrate. Ten nmol/L of commercial uPA and scFv-scuPAs was incubated with 400 nmol/L of human glu-plasminogen (Sigma-Aldrich) and 1 mmol/L of S2251 (Chromogenix, Italy). Samples were measured using the Bio-Rad Benchmark Plus at a wavelength of 405 nm every 30 seconds over a period of 60 minutes.
Fibrin Zymography
SDS-PAGE-based fibrin zymography 20 was performed to evaluate plasminogen-dependent fibrinolytic activity of the targeted and nontargeted scFv-scuPA. Briefly, the commercial uPA and scuPA were subjected to SDS-PAGE. After electrophoresis, gels were washed in 2.5% Triton X-100 for 1.5 hours and then placed on top of a fibrin/agarose-plasminogen matrix. The washed SDS-PAGE gel was then overlaid onto the exposed agarose gel and incubated in a humidified 37°C oven until lytic zones were evident. Images were captured at various incubation times using a flatbed document scanner.
Light Transmission Aggregometry
Ninety-six-well plate light transmission aggregometry was performed using 100 μL of PRP. PRP were incubated with abciximab, scFv-scuPA, scFv SCE5 alone, or commercial uPA and then activated with 10 μmol/L ADP. Platelet-poor plasma was obtained by centrifugation of blood at 1000g for 10 minutes at room temperature. Light transmission was adjusted to 0% with PRP and 100% with platelet-poor plasma. To differentiate the effects of scFv from those of urokinase, 200 μmol/L of the urokinase blocker amiloride 21 was added. Light transmission aggregometry was measured using the Bio-Rad Benchmark Plus at wavelength of 595 nm. Samples were measured every 30 seconds for 60 minutes.
Flow Chamber Adhesion Assay
Flow chamber in vitro adhesion assays were performed with glass capillaries or microfluidic flow channels, which were coated overnight with collagen. Whole blood was perfused through the capillaries or channels to form microthrombi. Binding of scFv-scuPAs was observed via staining with anti-His-488. Fibrin degradation was demonstrated using Oregon-Green Fibrinogen (Invitrogen). The microthrombi were visualized with the IX81 Olympus microscope and Cell^P 1692 software.
In Vivo Mouse Experiments
Male C57BL/6 mice and plasminogen-knockout mice (plg −/− mice; Jackson Laboratories) were maintained at the Alfred Medical Research and Education Precinct Animal Services and assigned randomly to the different groups. The amount of targeted and nontargeted scFv-scuPA for injection was calculated according to units per gram body weight of the animals. The animals were anesthetized, shaved, and placed on a 37°C heater mat to prevent hypothermia. All experiments involving animals were approved by the Alfred Medical Research and Education Precinct Animal Ethics Committee (E/1160/2011/B).
Femoral Vein Catheterization and Ferric Chloride Injury Model for Doppler Flow Velocity Measurement
A catheter was placed into the femoral vein to facilitate injection. A small filter paper saturated with 10% ferric chloride was placed under the carotid artery of the animal for 3 minutes to induce an occlusive thrombus. 22 Animals were injected with either constructs or controls 1 minute before the injury. The nano-Doppler flow-probe (0.5VB; Transonic, Japan) was placed under the carotid artery postinjury to measure thrombotic occlusion.
Intravital Microscopy of the Mesenteric Arterioles in Mice
Intravital microscopy was performed as previously described. 23 Briefly, the mesentery was exteriorized through a midline abdominal incision. Six percent ferric chloride was used to induce thrombus formation on mesenteric arterioles. Binding of the scFv-scuPAs conjugated with Cy3 fluorescence dye (Lumiprobe) was monitored using the fluorescence channel on the Nikon A1r confocal microscope (Nikon, Japan).
Assessment of Tail Bleeding Time
An incision to reveal the left jugular vein was made to insert a catheter to facilitate injections. One minute after injecting commercial uPA, scFv-scuPAs, or vehicle, the tail was transected 5 mm from the tip and immediately submersed in saline at 37°C. The bleeding time was monitored and recorded as the time needed for the cessation of visible blood stream for 1 minute.
In Vivo Ultrasound Molecular Imaging of Carotid Artery Thrombolysis
Ultrasound of animals was performed with a Vevo770 high-resolution imaging system (VisualSonics Inc, Canada) using a 40-MHz RMV704 transducer. Animals were placed on the imaging station after 6% ferric chloride injury was performed to the left carotid artery. Videos and images were acquired before, during, and at several time points after injecting 1.5×10 7 targeted microbubbles (ligand-induced binding sides-targeted microbubbles, LIBS-MBs) specific for activated platelets (targeting the ligand-induced binding site on activated GPIIb/IIIa) in a total volume of 100 μL. We have recently established this ultrasound imaging methodology for the assessment of thrombosis and thrombolysis. 19 We injected 500 U/g of uPA (Medac, Germany), 75 U/g of scFv-scuPA, or saline as vehicle control. Repetitive ultrasound imaging sequences were performed every 5 minutes for an hour after thrombolysis. Analysis was performed using a linear contrast agent imaging software (VisualSonics Inc).
In Vivo Ultrasound Molecular Imaging of Carotid Artery Thrombolysis Using plg
−/− Mice plg −/− Mice were placed on the VisualSonics imaging station after 6% ferric chloride injury was performed to the left carotid artery. Images were acquired before injection of LIBS-MBs. Thereafter, we injected 75 U/g of scFv SCE5 -scuPA or scFv mut -scuPA. Repetitive ultrasound imaging sequences were performed every 5 minutes for 30 minutes. A 150-μL bolus of 100 μg/mL human plasminogen (Sigma-Aldrich) was injected at 30-minute time point and repetitive imaging sequences continued for another 30 minutes. Analysis was performed using a linear contrast agent imaging software.
Statistical Analysis
Unless otherwise specified, data are expressed as mean±SEM. Flow cytometry, flow chamber, and data for thrombolysis were analyzed with 2-way repeated-measures ANOVA using Bonferroni multiple comparison post-test. All analyses containing >2 groups were corrected by post hoc analysis, and the corrected P values are given. Statistical analyses were performed using GraphPad Prism 5.0.
Results

Cloning and Purification of scFv-scuPA Constructs
The success of DNA amplification and restriction digest of scFv-scuPA fragments was evaluated by electrophoresis (Online Figure I ). Both constructs were visualized between 1.5 and 2 kbp marker after amplification with PCR and restriction digest. The pSectag2A plasmid was visualized at ≈5 kbps after single-cut restriction digest. After the respective constructs were cloned into the pSectag2A plasmid, transformed, and purified, they were analyzed by gel electrophoresis. The sequences of both fusion constructs were confirmed via DNA sequencing. After production of the scFvs, SDS-PAGE and Western blot were used to prove successful purification (Online Figure IIA and IIB). Western blot was also used to demonstrate the digestion of scuPA after the addition of plasmin (Online Figure IIB) .
Binding of Targeted scuPA to CHO Cells In Vitro
The specificity of scFv SCE5 -scuPA was also observed under static adhesion conditions. Direct fluorescence staining using anti-His-488 demonstrated binding of scFv SCE5 -scuPA to the activated GPIIb/IIIa-expressing CHO cells but not on either 
Evaluation of the Functionality of scFv-scuPA by Flow Cytometry
To confirm retained binding capacity of scFv to ADP-activated platelets, the functionality of scFv-scuPA was evaluated with anti-His-488 ( Figure 2 SCE5 was also confirmed with collagen-related peptide and thrombin receptor-activating peptide-activated platelets (Online Figure IVA) . Platelet activation by these platelet agonists was demonstrated using PAC1 and anti-CD62P fluorescence staining (Online Figure IVB 
In Vitro Evaluation of scFv-scuPA Activity in Platelet Aggregation
Light transmission aggregometry in a 96-well plate assay was performed to determine the ability of recombinant ) or scFv mut -scuPA. However, fibrinogen-FITC did not bind to activated platelets in the presence of scFv SCE5 -scuPA. C, Competitive assays using PAC1-FITC. PAC1-FITC binds to activated GPIIb/IIIa on activated platelets when incubated with the negative control (PBS with 2 mmol/L Ca 2+ and Mg 2+ ) or scFv mut -scuPA. However, PAC1-FITC did not bind to activated platelets in the presence of scFv SCE5 -scuPA (mean±SD; **P<0.01, ***P<0.001). These assays were analyzed with a 2-way repeatedmeasures ANOVA with the Bonferroni post-test. scFv indicates single-chain antibody fragments; and scuPA, single-chain urokinase plasminogen activator. fusion proteins to inhibit platelet aggregation. High concentrations of scFv SCE5 alone (5 and 10 μg/mL) and equimolar amounts of scFv SCE5 -scuPA (10 and 20 μg/mL) demonstrated a strong inhibition of ADP-induced platelet aggregation as opposed to scFv mut -scuPA, which showed no inhibitory effect (Figure 3A ; n=4; P<0.001). At lower concentrations, scFv SCE5 alone (0.1 and 1 μg/mL) and equimolar amounts of scFv SCE5 -scuPA (0.2 and 2 μg/mL) would not inhibit platelet aggregation. Platelet aggregation also was not inhibited with 100 or 200 U of commercial uPA (P<0.001). Similar results were obtained when 200 μmol/L of amiloride was used to block the function of scuPA ( Figure 3B ), demonstrating that urokinase has no effect on thrombus formation in this assay.
Non-expressing CHO cells
In Vitro Evaluation of the Urokinase Activity of scFv-scuPA 
In Vitro Evaluation for the Conversion of Plasminogen to Plasmin Using scFv-scuPA
The conversion of plasminogen to plasmin was monitored using the S2251 amidolytic assay (Online Figure VIB) . Both scFv-scuPA versions and the commercial uPA at 10 nmol/L generated plasmin activity. uPA-dependent plasmin generation was blocked in the presence of 200 μmol/L of the urokinase inhibitor amiloride. SDS-PAGE fibrin zymography was also performed to demonstrate the direct digestion of fibrin (Online Figure VIC) . Commercial uPA produced a lytic zone as expected at ≈55 kDa. scFv SCE5 -scuPA and scFv mut -scuPA produced a lytic zone at ≈70 kDa.
Binding to Activated Platelets and Fibrin Degradation With Targeted scuPA to Microthrombi In Vitro
Targeting of scFv SCE5 -scuPA was determined by binding performance in vitro in a flow chamber adhesion experiment with microthrombi. Fluorescence staining using anti-His-488 demonstrated binding of scFv SCE5 -scuPA but not with scFv mut -scuPA ( Figure 4A ). Fibrin degradation was observed when scFv SCE5 -scuPA and a high dose of commercial uPA was used, but not with scFv mut -scuPA ( Figure 4B ). Using 2 μg/mL of scFv SCE5 -scuPA, fibrin degradation was observed specifically around platelet aggregates (Online Figure VII) .
Evaluation of scFv-scuPA Binding to Thrombi In Vivo
Binding of scFv-scuPA was determined by intravital microscopy in a ferric chloride-induced thrombosis model in the mesenteric arterioles of mice. The binding of scFv SCE5 -scuPA conjugated with the fluorescent dye Cy3 to developing thrombi could be demonstrated, whereas no fluorescence was observed with scFv mut -scuPA ( Figure 4C ).
In Vivo Evaluation of scFv-scuPA for Prophylactic Fibrinolysis
Thrombi were induced in the carotid artery of mice using 10% ferric chloride for 3 minutes. Blood flow was measured by a nano-Doppler flow-probe and used as an indicator of occlusive thrombus ( Figure 5 ). Saline was injected as a negative control, and 500 U/g of commercial uPA was used as a positive control. Lower concentrations of scFv SCE5 -scuPA (0.2 and 2 μg/mL) and equimolar amounts of scFv SCE5 alone did not show the inhibition of platelet aggregation. Platelet aggregation was not inhibited with commercial uPA. B, Aggregometry after the addition of 200 μmol/L of the urokinase inhibitor amiloride further demonstrating that urokinase has no effect on thrombus formation in this assay. scFv SCE5 -scuPA (10 and 20 μg/mL) and equimolar amounts of scFv SCE5 alone (5 and 10 μg/mL) demonstrated the inhibition of ADP-induced platelet activation as opposed to scFv mut -scuPA (n=3; ***P<0.001).
Lower concentrations of scFv SCE5 -scuPA (0.2 and 2 μg/mL) and equimolar amounts of scFv SCE5 alone did not show the inhibition of platelet aggregation. Platelet aggregation was not inhibited with commercial uPA. scFv indicates single-chain antibody fragments; and scuPA, single-chain urokinase plasminogen activator.
uPA throughout the observation period. Similar results were obtained at 30 minutes.
In Vivo Assessment of Bleeding Time of scFv-scuPA
Bleeding times were evaluated by surgical tail transection ( Figure 6 ). Commercial uPA at 500 U/g considerably prolonged bleeding compared with vehicle control (saline). In contrast, a lower dose of 75 U/g of scFv SCE5 -scuPA, scFv mut -scuPA, and commercial uPA minimized bleeding time. The lower dose of scFv SCE5 -scuPA (75 U/g) had an antithrombolytic effect without prolonging bleeding time.
In Vivo Molecular Ultrasound Imaging of Thrombolysis
Imaging of the mouse carotid artery on ultrasound typically shows luminal blood as black or dark color, and microbubbles appear as a bright white color in the lumen. The thrombus was visualized as a white and bright signal after injection with platelet-targeted ultrasound contrast (LIBS-MB) on realtime ultrasound imaging. The baseline area before injection of uPA was set to 100%, and the area was calculated every 5 minutes for 60 minutes ( Figure 7 ). The targeting ability of 75 U/g of scFv SCE5 -scuPA is demonstrated by ultrasound imaging; as such, a reduction in thrombus size was observed after its administration. Treatment with scFv SCE5 -scuPA (75 U/g) significantly reduced thrombus size after 60 minutes, whereas no significant difference was observed in the scFv mut -scuPA (75 U/g) treatment group (36.8±4.6 versus 81.1±2.6 AU; mean%±SEM; P<0.001; n=3; Figure 7 ; Online Videos I and II). Thrombolysis was observed via ultrasound imaging using 500 U/g of commercial uPA. The ability of scFv SCE5 -scuPA to target and dissolve the thrombus was compared against mice injected with a higher dose of commercial uPA. There were no significant differences between groups of mice treated with 500 U/g commercial uPA and those treated with 75 U/g of scFv SCE5 -scuPA over a period of 60 minutes (40.05±9.2 versus 36.8±4.6 AU; ns; n=3). The thrombolytic ability of scFv SCE5 -scuPA was also compared with the control group where saline was administrated over a period of 60 minutes. scFv SCE5 -scuPA caused a reduction in thrombus size at 60 minutes postadministration, compared with control (36.8±4.6 versus 99.2±1.3 AU; P<0.001; n=3). This control group was also compared against the nontargeted treatment using 75 U/g of scFv mut -scuPA. Although postadministration of scFv mutscuPA showed some reduction in the thrombus area, it was not significantly smaller than those injected with saline (81.1±2.6 versus 99.2±1.3 AU; ns; n=3).
In Vivo Ultrasound Molecular Imaging of Carotid
Artery Thrombolysis on plg −/− Mice plg −/− Mice were subjected to ferric chloride-induced thrombosis. Mice were then administered either scFv SCE5 -scuPA (75 U/g) or scFv mut -scuPA (75 U/g). Over a 30-minute period, there was no change in thrombus size in both groups of animals (96.0±0.1 versus 98.55±0.1 AU; mean%±SEM; ns; n=3). However, when plg −/− mice were reconstituted with human plasminogen (100 μg/mL; 150 μL bolus at 30-minute time point), mice treated with scFv SCE5 -scuPA developed a significant thrombus size reduction, whereas no significant difference was observed in plg −/− mice treated with scFv mutscuPA (23.1±1.5 versus 92.1±2.2 AU; mean%±SEM; P<0.001; n=3; Figure 8 ).
Discussion
Thrombolysis has been widely used as a therapy in acute myocardial infarction, ischemic stroke, as well as pulmonary embolism. 4, 24 However, limitations in thrombolytic efficacy, neurotoxicity of tPA, 25 and bleeding complications have restricted overall use.
6, 26 The administration of anticoagulants in combination with fibrinolytic agents, in particular, has shown little improvement in mortality, safety, and efficacy. 27 Therefore, research into more effective treatments is required, which could overcome the challenges associated with current fibrinolytic therapy. Targeting activated platelets with antibody-mediated delivery of thrombolytic drugs can provide an effective and safe alternative. This ideal agent would: (1) allow a low concentration in systemic circulation, thereby eliminating bleeding complications, and (2) enrich by targeting at the site of thrombus, thereby being present in localized high concentrations to lyse the clot.
In this study, we conjugated a highly specific scFv that binds to the activated platelet integrin receptor GPIIb/IIIa and recombinant scuPA. Our data demonstrate that scuPA delivery to activated platelets allows local enrichment of fibrinolytic agents at the site of the developing or existing thrombus, thereby increasing fibrinolytic potency without increasing side effects. Through in vitro assays, we provide evidence that both scFv and scuPA retain their individual function in the fusion molecule. In vivo evaluation of these targeted fibrinolytics as both a prophylactic and a therapeutic agent showed plasminogen-dependent inhibition of thrombus growth as well as reduction in thrombus size via molecular ultrasound imaging. A low dose of 75 U/g of platelet-targeted scuPA was sufficient for localized thrombolysis, which was not achieved using nontargeted scuPA or commercial uPA at the same dose. The same effects were only achieved using urokinase at 500 U/g. We did not observe increased bleeding at the effective dose of the novel targeted scuPA, compared with an equally effective higher dose of nontargeted scuPA, which resulted in a significantly prolonged bleeding time. This antithrombotic effect of a low dose of 75 U/g of platelettargeted scuPA was more potent than the combination of equimolar nontargeted scuPA and the activation-specific anti-GPIIb/IIIa scFv SCE5 . This indicates that the superior antithrombotic effect of the fusion protein scFv SCE5 -scuPA can be attributed to the antibody targeting of scuPA to activated GPIIb/IIIa on activated platelets and the resulting local enrichment of scuPA at the thrombus. If a stronger antiplatelet effect is required, a dual effect composed of effective platelet inhibition and low-dose targeted fibrinolysis would be attractive and could be achieved with the coadministration of activation-specific anti-GPIIb/IIIa scFv alone. For a potential human therapy, the optimal dosing regimen would have to be determined in clinical trials. Notably, the combination of low-dose targeted fibrinolytic and activation-specific platelet inhibition would not be expected to have similar bleeding problems as seen in clinical trials with nontargeted fibrinolytics and nonactivation-specific GPIIb/IIIa inhibitors. 27 Early work mainly focused on the use of full monoclonal antibodies targeting specific components of the clot, such as fibrin or platelets. Indeed, in vivo studies have shown greater antithrombotic therapy with the use of fibrin-targeting thrombolytics. 28, 29 It has also been shown that potent fibrin targeting during thrombolysis has resulted in a high plasminogen concentration on the surface of the clot. 30 Our study focuses on platelets, because activated platelets are an obvious target for the enrichment of thrombolytics at the clot. To explore the advantages of targeting PAs to platelets, monoclonal antibodies directed against both GPIIb/IIIa and the ligand-binding epitope of GPIIb/ IIIa have been reported. 31 GPIIb/IIIa is the most abundant platelet receptor with 50 000 to 80 000 glycoproteins per platelet and, thus, constituting ≈2% of the amount of total platelet protein. 32 Despite increasing the potency by fusing PAs to monoclonal antibodies or Fab fragments, chemical conjugation has several disadvantages, including the inactivation of enzymatic sites by the harsh chemical conditions for conjugating, which can reduce efficacy. 31, 33 In addition, the large size of the antibody fusion constructs hampered tissue penetration.
To overcome these problems, recombinant fusion technology was used to avoid chemical conjugation, thereby preserving the activity of the construct. Antibody fragments such as scFvs are preferred moieties for the construction of recombinant fusion constructs because they are small, minimally immunogenic, and the cost of production is generally low. 34, 35 Antibody-targeted delivery also eliminates the dependence on the specificity of certain PAs, such as tPA, for the components of clots such as fibrin. Still the gold standard therapy for acute ischemic stroke, 36 tPA is neurotoxic, 25 and the use of urokinase or desmoteplase avoids these complications inherent to tPA. 37, 38 This has the potential to widen the currently very narrow therapeutic window for stroke thrombolysis of 3 to 4 hours. 6 The truncated, low-molecular-weight form scuPA is the preferred entity over full-length urokinase because it provides a smaller size with improved thrombus accessibility, no immunogenicity, and similar fibrinolytic potency. 39 In addition to fibrin-and platelet-targeting approaches, there are several other components of the vasculature and blood that have been targeted, such as platelet endothelial cell adhesion molecule-1, glycophorin A on RBCs, and thrombomodulin, to anchor PAs to the arterial or venous lumen. [40] [41] [42] [43] Platelet endothelial cell adhesion molecule-1 fused with urokinase in a model of cerebrovascular thromboembolism mediated almost complete clot lysis without exacerbating the characteristic side effects such as intracerebral hemorrhage. 44 Targeting RBCs was shown to have effective prophylaxis against arterial and venous thrombosis for ≈24 hours. 42 Although targeting platelet endothelial cell adhesion molecule-1 or RBCs has shown successful thrombolysis, they do not serve as exclusive targets because of ubiquitous expression. We have previously reported that scFvs against fibrin conjugated to scuPA, 45 or against platelets conjugated to an anticoagulant, 22 are predominantly active only at the site of the clot, allowing increased potency. In the present study, we have expanded our work to a scFv fusion molecule, which delivers scuPA activation specific to the GPIIb/IIIa platelet receptor. On activation, GPIIb/IIIa undergoes a conformation change, which allows a high-affinity state for fibrinogen binding, resulting in platelet aggregation and thrombus formation. 9, 15 This property is ideal for specifically targeting activated platelets. The scFv SCE5 used in this work is exclusive in its specificity for the activated conformation of GPIIb/IIIa thereby, representing a unique targeting tool. 15, 16, 23 In addition to our well-established Doppler flow measurements 15, 22 allowing the assessment of vessel patency, we also applied a recently developed real-time ultrasound method with scFv-targeted microbubbles used as echo enhancers. 19 The small size of scFv has advantages for molecular imaging because it provides a better access to the targeted epitopes. In contrast to the anti-GPIIb/IIIa scFv used in the scuPA fusion construct, the scFv on the microbubbles binds to LIBS on GPIIb/IIIa, preserving the ligand binding function. This new molecular imaging approach allows the unique real-time and direct monitoring of the success and extent of thrombolysis, and it holds promise to substantially facilitate further research in thrombogenesis and especially thrombolysis. Furthermore, this technique is also highly promising for clinical use. It is noninvasive, inexpensive, and most importantly provides real-time analysis of vessel occlusion and reopening in an emergency setting. Direct ultrasound imaging of changes in thrombus size is a technique that could have broad clinical applications in detecting the success or failure of therapeutic interventions in thrombotic disease and, thus, provide major benefits for patients.
The potential clinical use of these targeted fusion proteins for the prevention and treatment of stroke, myocardial infarction, and venous thrombosis presents a novel strategy for highly effective thrombolysis. The expected reduction of bleeding complications could lead the way out of the current stagnation in the field of fibrinolytic therapy. Our data also have interesting implications for the potential use of a fibrinolytic drug for prophylaxis/prevention of thrombosis. Monoclonal antibodies (eg, Humira) are increasingly used as subcutaneous drugs for self-administration by patients. 46 This opens the possibility that recombinant fusion proteins such as scFv SCE5 -scuPA could potentially be used for thromboprophylaxis. More preclinical and clinic research is warranted to investigate the feasibility of such an application. Furthermore, the described molecular ultrasound imaging with platelet-targeted microbubbles allows precise monitoring of interventional success.
Conclusions
This study demonstrates the successful generation of a novel recombinant single-chain antibody-scuPA fusion protein, specifically targeting activated platelets. The function of both components of the fusion protein, thrombolytic activity and antibody binding, to activated GPIIb/IIIa was preserved. In vivo evaluation of this targeted fibrinolytic agent, in comparison to clinically used nontargeted fibrinolytic agents, showed that a low systemic concentration of the fusion protein allows enrichment of fibrinolytic activity at the site of the thrombus and thus the potentiation of fibrinolytic activity. Most importantly, this could be achieved without prolonging bleeding time. Therefore, this novel fibrinolytic agent promises to overcome the current limitations in thrombolytic therapy associated with the risk of bleeding complications. It has the potential to break the fatal link between increased fibrinolytic potency and bleeding complications. This targeting strategy also allows considering the application of a fibrinolytic drug for thromboprophylaxis, an approach that warrants further preclinical and potential clinical testing.
